Brigatinib (Alunbrig™)

Status: Solid Tumor and NF2 Clinical Trial

Legal Status:

℞ - Trial

Administered By:

Pill - Oral

Tumor Target:

Solid Tumors; Schwannoma, Meningioma

Inhibits:

anaplastic lymphoma kinase (ALK) and
epidermal growth factor receptor (EGFR) inhibitor

Brigatinib (Alunbrig™) is a clinical trial tumor drug treatment listed for solid tumors. Early mouse trial studies suggest brigatinib may have good results with the reduction of size in solid tumors including; schwannoma and meningioma.

During the mouse trials no growth was seen with long treatment breaks, followed by continued size reduction when the treatment continued again later. If this holds for human trials, breaks for healing from possible side effects or for treatments of other health issues.

Treatment Availability

This solid tumor trial is available to individuals with neurofibromatosis type 2 (NF2), or other solid tumors.

Results in the Mouse Trial Phase

In mouse trials with brigatinib tumors reduced in size and remained stable during three (3) month breaks in treatment.

Side Effects

No known side effects at this time except possible kidney or liver failure, like all tumor drug treatments.

Source Information

• CTF. "Boston NF Symposium. 2019" (3/2019)
  https://www.facebook.com/events/1266734493474401/
• ChemSpider. "Brigatinib" ID34982928
• Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial"
  https://ascopubs.org/doi/full/10.1200/JCO.2016.71.5904